Fever-Tree, the world's leading supplier of premium carbonated mixers, announces that on 6 December 2018, Jeff Popkin, Non-Executive Director of the Company, purchased, in aggregate, 2,933 ordinary shares in the Company at a volume weighted average price of US $29.54 per ordinary share via US OTC Markets.
Numis Securities - Nominated Adviser and Joint Broker
Alex Ham / Matt Lewis
Investec Bank plc - Joint Broker
+44 (0)20 7260 1000
+44 (0)20 7597 5970
Notes to Editors:
Fever-Tree is the world's leading supplier of premium carbonated mixers for alcoholic spirits by retail sales value, with distribution to over 70 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers to hotels, restaurants, bars and cafes ("On Trade") as well as selected retail outlets ("Off Trade").
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations
Details of the person discharging managerial responsibilities/person closely associated
Reason for the notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Fevertree Drinks plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Fever Tree equity trading OTC as FQVTF
Nature of the transaction
Acquisition of FQVTF equity via OTC
Price(s) and volume(s)
Date of the transaction
Place of the transaction
US OTC market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...